N-of-One Becomes Oracle Silver Level Partner

February 18, 2015 09:00 AM Eastern Standard Time
LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., a leader in clinical interpretation for precision medicine in oncology, today announced that it has become a Silver Partner in Oracle PartnerNetwork (OPN) Specialized program. By attaining Silver Level membership, N-of-One will benefit from integrated access of N-of-One clinical interpretation solutions with the highly scalable Oracle Health Sciences Translational Research Center. Oracle's comprehensive platform aggregates omics data and data from electronic health records and can be leveraged to accelerate biomarker identification for drug discovery and clinical development, to facilitate translational medicine research.

N-of-One, combined with Oracle's TRC, can now add N-of-One clinical interpretation to enable the delivery of molecularly guided treatment strategies to the point of care for providers that are launching and growing a precision medicine program.

N-of-One provides clinical interpretation and analysis of next-generation sequencing (NGS) and companion diagnostic test results of each patient's cancer. N-of-One's clinical interpretation links the relevant biological and clinical evidence and insights related to the mutation profile of each tumor to possible therapeutic strategies for the physician.

With this new relationship, N-of-One can gain the ability to integrate its clinical interpretation solutions with Oracle Health Sciences Translational Research Center, a comprehensive platform that normalizes, aggregates, controls, and analyzes all the diverse clinical and molecular data needed to support the complete biomarker lifecycle. This allows mutual customers to incorporate all relevant clinical and scientific data, including patient-specific EMR content, in the clinical analysis to identify each patient's therapeutic options for physician treatment decisions.

"We are pleased to work closely with the talented team at Oracle Health Sciences as they develop the Oracle Health Sciences Translational Research Center platform and other precision medicine tools that easily adapt to and address clinical environments for oncology patients," said Chris Cournoyer, CEO of N-of-One. "As precision medicine becomes an integral part of providing outstanding cancer care, oncologists increasingly are looking for insight on molecularly-guided therapeutic options for each patient."

About N-of-One

N-of-One, a leader in enabling precision medicine for oncology, leverages its world-class team of experts coupled with a highly proprietary platform that allows us to provide clinical solutions and services , such as molecular interpretation, to clinicians at the point of care. N-of-One's team of experts has interpreted thousands of samples for oncologists and patients worldwide, through partnerships with leading diagnostic companies, hospital systems, directly to oncologists and through employee access benefit programs. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.

About Oracle PartnerNetwork

Oracle PartnerNetwork (OPN) Specialized is the latest version of Oracle's partner program that provides partners with tools to better develop, sell and implement Oracle solutions. OPN Specialized offers resources to train and support specialized knowledge of Oracle products and solutions and has evolved to recognize Oracle's growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to differentiate through Specializations. Specializations are achieved through competency development, business results, expertise and proven success. To find out more visit http://www.oracle.com/partners.

###

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates.

Contacts
The Yates Network
Kathryn Morris, 845-635-9828
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.